SCHEMBL16570933

SCHEMBL16570933

C[C@H]1CN(c2ccc(Nc3ncc4cnn(S(=O)(=O)c5ccccc5Cl)c4n3)cc2)CCN1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FGFR4 P22455 6/20 0.55
WEE1 P30291 8/20 0.52
PTK2 Q05397 1/20 0.43
AXL P30530 1/20 0.43
NEK2 P51955 1/20 0.43
FGFR1 P11362 1/20 0.43
FGFR2 P21802 1/20 0.43
FGFR3 P22607 1/20 0.43
CDK4 P11802 2/20 0.43
CCND1 P24385 2/20 0.43
CDK6 Q00534 1/20 0.43
ADRA2A P08913 1/20 0.42
ADRA2B P18089 1/20 0.42
ADRA2C P18825 1/20 0.42
MAPK8 P45983 1/20 0.42
MAPK9 P45984 1/20 0.42
MAPK10 P53779 1/20 0.42
CCNA2 P20248 1/20 0.42
CDK2 P24941 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16571009 1.00 FGFR4 (0.55) FGFR4WEE1PTK2AXLNEK2
SCHEMBL16570934 1.00 FGFR4 (0.55) FGFR4WEE1PTK2AXLNEK2
SCHEMBL16570644 0.90 WEE1 (0.45) FGFR4WEE1FGFR1FGFR2FGFR3
SCHEMBL16570641 0.90 WEE1 (0.45) FGFR4WEE1FGFR1FGFR2FGFR3
SCHEMBL16570741 0.90 WEE1 (0.45) FGFR4WEE1FGFR1FGFR2FGFR3
SCHEMBL16570777 0.88 FGFR4 (0.59) FGFR4WEE1FGFR1FGFR2FGFR3
SCHEMBL16580980 0.88 WEE1 (0.44) FGFR4WEE1FGFR1FGFR2FGFR3
SCHEMBL16580737 0.88 WEE1 (0.44) FGFR4WEE1FGFR1FGFR2FGFR3
SCHEMBL17958755 0.88 WEE1 (0.44) FGFR4WEE1FGFR1FGFR2FGFR3
SCHEMBL16570888 0.87 FGFR4 (0.73) FGFR4WEE1FGFR1FGFR2FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 US claimed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 WO claimed
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 US disclosed
WO-2015038417-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2015-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS SRC, PTK2, FYN FGFR4 385/4885WEE1 1512/4885PTK2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.